HK1126200A1 - Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor - Google Patents

Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor

Info

Publication number
HK1126200A1
HK1126200A1 HK09104609.6A HK09104609A HK1126200A1 HK 1126200 A1 HK1126200 A1 HK 1126200A1 HK 09104609 A HK09104609 A HK 09104609A HK 1126200 A1 HK1126200 A1 HK 1126200A1
Authority
HK
Hong Kong
Prior art keywords
isoquinoline
histamine
benzo
antagonists
receptor
Prior art date
Application number
HK09104609.6A
Other languages
English (en)
Inventor
Martin Juan Antonio Diaz
Arenales Beatriz Escribano
Bargueno Maria Dolores Jimenez
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1126200A1 publication Critical patent/HK1126200A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
HK09104609.6A 2005-11-24 2009-05-20 Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor HK1126200A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05111248A EP1790646A1 (fr) 2005-11-24 2005-11-24 Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
PCT/EP2006/012246 WO2007060027A1 (fr) 2005-11-24 2006-11-22 Derives de isoquinoline et benzo[h]isoquinoline, leur preparation et leur utilisation en therapeutique en tant qu’antagonistes du recepteur de l’histamine h3

Publications (1)

Publication Number Publication Date
HK1126200A1 true HK1126200A1 (en) 2009-08-28

Family

ID=36295552

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09104609.6A HK1126200A1 (en) 2005-11-24 2009-05-20 Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor

Country Status (25)

Country Link
US (1) US7678807B2 (xx)
EP (2) EP1790646A1 (xx)
JP (1) JP5165578B2 (xx)
KR (1) KR101386318B1 (xx)
CN (1) CN101312961B (xx)
AR (1) AR057615A1 (xx)
AT (1) ATE531707T1 (xx)
AU (1) AU2006316706B2 (xx)
BR (1) BRPI0618971A2 (xx)
CA (1) CA2630655C (xx)
CY (1) CY1112386T1 (xx)
DK (1) DK1960387T3 (xx)
DO (1) DOP2006000253A (xx)
ES (1) ES2376894T3 (xx)
GT (1) GT200600490A (xx)
HK (1) HK1126200A1 (xx)
IL (1) IL191214A (xx)
PE (1) PE20070827A1 (xx)
PL (1) PL1960387T3 (xx)
PT (1) PT1960387E (xx)
RU (1) RU2418794C2 (xx)
SI (1) SI1960387T1 (xx)
TW (1) TW200738681A (xx)
UY (1) UY29971A1 (xx)
WO (1) WO2007060027A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
JP5968307B2 (ja) 2010-05-11 2016-08-10 サノフイ 置換フェニルシクロアルキルピロリジン（ピペリジン）スピロラクタム類及びアミド類、それらの製造及び治療的使用
WO2011143148A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
EP2569296A1 (en) * 2010-05-11 2013-03-20 Sanofi Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
AR081382A1 (es) * 2010-05-11 2012-08-29 Sanofi Aventis Derivados de n-heterocicloalquil bipirrolidinilfenil amida sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central.
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL343424A1 (en) * 1998-04-10 2001-08-13 Japan Tobacco Inc Amidine compounds
WO2000023437A1 (fr) * 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Composes azotes hererocycliques condenses; procede de fabrication et agents les renfermant
WO2002076925A2 (en) * 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
NL1020155C2 (nl) * 2002-03-11 2003-09-17 Bernardus Johannes Jos Bekkers Inrichting voor het dragen van een golftas alsmede werkwijze voor het vervaardigen ervan.
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
US20060089347A1 (en) * 2002-08-20 2006-04-27 Eli Lilly And Company Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses
GB0408083D0 (en) * 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique

Also Published As

Publication number Publication date
RU2418794C2 (ru) 2011-05-20
BRPI0618971A2 (pt) 2011-09-20
EP1790646A1 (fr) 2007-05-30
US20080269199A1 (en) 2008-10-30
PT1960387E (pt) 2012-02-09
CY1112386T1 (el) 2015-12-09
PE20070827A1 (es) 2007-08-17
JP5165578B2 (ja) 2013-03-21
RU2008125136A (ru) 2009-12-27
AU2006316706A1 (en) 2007-05-31
CA2630655A1 (fr) 2007-05-31
SI1960387T1 (sl) 2012-03-30
KR101386318B1 (ko) 2014-04-17
AU2006316706B2 (en) 2012-05-03
JP2009517357A (ja) 2009-04-30
ATE531707T1 (de) 2011-11-15
PL1960387T3 (pl) 2012-03-30
UY29971A1 (es) 2007-06-29
DK1960387T3 (da) 2012-02-27
EP1960387A1 (fr) 2008-08-27
CA2630655C (fr) 2014-08-26
DOP2006000253A (es) 2007-07-15
ES2376894T3 (es) 2012-03-20
CN101312961A (zh) 2008-11-26
GT200600490A (es) 2007-07-06
AR057615A1 (es) 2007-12-05
CN101312961B (zh) 2012-04-11
KR20080076910A (ko) 2008-08-20
US7678807B2 (en) 2010-03-16
TW200738681A (en) 2007-10-16
WO2007060027A1 (fr) 2007-05-31
EP1960387B1 (fr) 2011-11-02
IL191214A (en) 2012-07-31

Similar Documents

Publication Publication Date Title
PL2176252T3 (pl) 2,3-dihydrobenzo[1,4]dioksyn-2-ylometylopochodne jako antagoniści receptora alfa2c do zastosowania w leczeniu chorób obwodowego i ośrodkowego układu nerwowego
IL195510A0 (en) Urea derivatives of tropane, their preparation and their therapeutic application
IL182695A0 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
PL1951661T3 (pl) Antagoniści receptora glukagonu, wytwarzanie i terapeutyczne zastosowania
ZA200700705B (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
PL1951658T3 (pl) Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne
AP1983A (en) Carboxamide derivatives as muscarinic receptor antagonists
SI1863476T1 (sl) Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
IL180770A0 (en) Oxopiperidine derivatives, preparation and therapeutic use thereof
HK1131779A1 (en) Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof
IL207356A0 (en) 5, 6 - bisaryl-2- pyridine - carboxamide derivatives, preparation thereof and therapeutic application thereof as antagonists for urotensine ii receptors
HK1126200A1 (en) Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor
IL180797A0 (en) Amino-tropane derivatives, preparation thereof and therapeutic use thereof
ZA201004644B (en) "derivatives of 6-heterocyclic-imidazo[1,2-a]pyrroine-2-carboxamides,preparation thereof and therapeutic application thereof"
ZA201100251B (en) Substituted 1-benzyl-cinnolin-4(1h)-one derivatives,preparation thereof,and therapeutic use thereof
ZA201000582B (en) 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives,preparation and therapeutic use thereof
HK1107340A1 (en) 4-arylmorpholin-3-one derivatives, preparation and therapeutic use thereof
SI1951659T1 (sl) Antagonisti glukagonskega receptorja, priprava in terapevtske uporabe

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161122